Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour Bio Starts China Trial of Autoimmune Treatment

publication date: Oct 5, 2020

Harbour BioMed, a China-US biopharma, has begun a China Phase II trial of HL161 (batoclimab) to treat two autoimmune diseases: myasthenia gravis and adult immune thrombocytopenia (ITP). HL161 is a novel mAb that inhibits FcRn to increase the half-life of immunoglobulin G antibodies. In 2017, Harbour in-licensed China rights to the candidate from HanAll Biopharma of Korea in a two-drug deal worth up to $81 million. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital